2024
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Murphy S, Goodrich E, Zhang S, Gaudet D, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. New England Journal Of Medicine 2024, 390: 1770-1780. PMID: 38587249, DOI: 10.1056/nejmoa2402309.Peer-Reviewed Original ResearchConceptsNon-HDL cholesterolElevated cardiovascular riskLevels of triglyceridesTriglyceride levelsCardiovascular riskModerate hypertriglyceridemiaApolipoprotein BAdverse eventsNon-high-density lipoprotein (HDL) cholesterolLow-density lipoprotein (LDL) cholesterolBaseline to 6 monthsMedian triglyceride levelsRisk of adverse eventsLDL cholesterol levelsHigh cardiovascular riskTriglyceride-rich lipoproteinsApolipoprotein C-IIISevere hypertriglyceridemiaMedian ageTriglyceride loweringPlatelet abnormalitiesNo significant changesPlaceboPhase 2bPrimary outcome
2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2019
Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity
de Lima-Junior J, Virginio V, Moura F, Bertolami A, Bertolami M, Coelho-Filho O, Zanotti I, Nadruz W, de Faria E, de Carvalho L, Sposito A. Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. Nutrition Metabolism And Cardiovascular Diseases 2019, 30: 254-264. PMID: 31753789, DOI: 10.1016/j.numecd.2019.09.017.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessBody mass indexCholesterol efflux capacityReduced cholesterol efflux capacityNon-diabetic individualsNon-obeseHDL-CIncreased values of BMIAtherosclerotic burdenEfflux capacityValues of body mass indexElevation of body mass indexProtective function of HDLIncreased BMIObesity-related declineInhibition of platelet aggregationHigh-density lipoprotein (HDLIncreased atherosclerotic burdenAssociated with carotid intima-media thicknessIncreased HDL-CDecreased HDL concentrationIntima-media thicknessFunction of HDLLipoprotein (HDLPlatelet aggregation inhibitionInhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
Cintra R, Moura F, Carvalho L, Barreto J, Tambascia M, Pecoits-Filho R, Sposito A. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Revista Da Associação Médica Brasileira 2019, 65: 70-86. PMID: 30758423, DOI: 10.1590/1806-9282.65.1.70.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsRisk of hypoglycemiaAntidiabetic therapySodium-glucose co-transporter 2High risk of hypoglycemiaIncreased risk of hypoglycemiaPrevalence of type 2 diabetes mellitusType 2 diabetes mellitusRenal proximal convoluted tubulesChronic kidney diseaseCo-morbid diseasesSystolic blood pressurePost hoc studyProximal convoluted tubulesReduced insulin sensitivitySGLT2i therapyMedian ageSodium-glucoseSodium reabsorptionOlder individualsClinical trialsIncreased riskKidney diseaseBlood pressureConvoluted tubules
2017
Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction
Moura F, Cintra R, Carvalho L, Santos S, Modolo R, Munhoz D, Quinaglia e Silva J, Coelho O, Nadruz W, Sposito A. Adverse outcome has a U-shaped relation with acute phase change in insulin sensitivity after ST-Elevation Myocardial Infarction. International Journal Of Cardiology 2017, 254: 16-22. PMID: 29246426, DOI: 10.1016/j.ijcard.2017.11.111.Peer-Reviewed Original ResearchConceptsST-elevation MIGRACE risk scoreInsulin sensitivity changesIntra-hospital deathMyocardial infarctionFollow-upMI hospitalizationAssociated with increased mortalityMarkers of glucose metabolismCox regression modelsInsulin provision therapyProspective cohortRisk scoreNet reclassification indexCardiac eventsAdverse cardiac eventsUpstream markersCox regressionAdverse outcomesHomeostasis model assessmentEstimate insulin sensitivityReclassification indexU-shaped relationStress hyperglycemiaInsulin sensitivity
2015
Coronary artery calcification score is an independent predictor of the no-reflow phenomenon after reperfusion therapy in acute myocardial infarction
Modolo R, Figueiredo V, Moura F, Almeida B, Quinaglia e Silva J, Nadruz W, Lemos P, Coelho O, Blaha M, Sposito A. Coronary artery calcification score is an independent predictor of the no-reflow phenomenon after reperfusion therapy in acute myocardial infarction. Coronary Artery Disease 2015, 26: 562-566. PMID: 26010531, DOI: 10.1097/mca.0000000000000269.Peer-Reviewed Original ResearchConceptsCoronary artery calcification scoreST-elevation myocardial infarctionCoronary artery calcificationMyocardial blush gradeTIMI flowAssociated with impaired reperfusionST-elevation myocardial infarction patientsCoronary angiographic severityCardiac computed tomographyConsecutive STEMI patientsTIMI flow ratesNonculprit coronary arteryCoronary thrombus burdenArtery calcification scoreAcute coronary syndromeNo-reflow phenomenonHigher heart rateCoronary blood flowCAC scoreOptimal reperfusionCalcification scoreClinical characteristicsAngiographic severityBlush gradeSTEMI patientsGlycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients
Moura F, Figueiredo V, Teles B, Barbosa M, Pereira L, Costa A, Carvalho L, Cintra R, Almeida O, Quinaglia e Silva J, Nadruz W, Sposito A, Study B. Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patients. Atherosclerosis 2015, 243: 124-130. PMID: 26385505, DOI: 10.1016/j.atherosclerosis.2015.09.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood GlucoseBrachial ArteryCoronary AngiographyC-Reactive ProteinDiabetes MellitusDietEndothelium, VascularFemaleFollow-Up StudiesGlycated HemoglobinHumansInflammationMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionNitric OxidePatient AdmissionPercutaneous Coronary InterventionProspective StudiesRisk FactorsROC CurveSensitivity and SpecificityTreatment OutcomeConceptsST-elevation myocardial infarctionFlow-mediated dilationNon-diabetic STEMI patientsC-reactive proteinSTEMI patientsEndothelial functionFollow-upInflammatory responseLong-term risk of MACEIncident diabetesLower HbA1cMedian follow-upClinical follow-upDecreased endothelial functionNon-diabetic patientsRisk of MACEAdverse cardiac eventsAdverse clinical outcomesIncreased inflammatory responseROC curve analysisSudden cardiac deathMeasured plasma glucoseNon-fatal MIPercutaneous coronary interventionLong-term risk
2014
Arterial tissue and plasma concentration of enzymatic-driven oxysterols are associated with severe peripheral atherosclerotic disease and systemic inflammatory activity
Virginio V, Nunes V, Moura F, Menezes F, Andreollo N, Rogerio F, Scherrer D, Quintão E, Nakandakare E, Petrucci O, Nadruz-Junior W, de Faria E, Sposito A. Arterial tissue and plasma concentration of enzymatic-driven oxysterols are associated with severe peripheral atherosclerotic disease and systemic inflammatory activity. Free Radical Research 2014, 49: 199-203. PMID: 25465091, DOI: 10.3109/10715762.2014.992894.Peer-Reviewed Original ResearchConceptsPeripheral arterial diseaseSevere peripheral arterial diseaseAtherosclerotic diseasePlasma C-reactive proteinFree of atherosclerotic plaquesSystemic inflammatory activityC-reactive proteinPeripheral atherosclerotic diseaseFree radical-mediated mechanismAtherosclerotic plaquesAdvanced atherosclerotic diseaseArterial tissueArtery diseaseInflammatory activityPlasma concentrationsEnzymatic stressDiseaseArteryRadical-mediated mechanismPlasmaPlaqueOxysterolsTissueShort-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial
Figueiredo V, Vendrame F, Colontoni B, Quinaglia T, Matos-Souza J, Moura F, Coelho O, de Faria E, Sposito A. Short-Term Effects of Extended-Release Niacin With and Without the Addition of Laropiprant on Endothelial Function in Individuals With Low HDL-C: A Randomized, Controlled Crossover Trial. Clinical Therapeutics 2014, 36: 961-966. PMID: 24768191, DOI: 10.1016/j.clinthera.2014.03.012.Peer-Reviewed Original ResearchConceptsEffects of extended-release niacinFlow-mediated dilationExtended-release niacinHDL-C levelsHDL-CEndothelial functionDay 7Reduced plasma concentrations of high-density lipoprotein cholesterolLow HDL-C levelsHDL-C levels <Plasma concentrations of high-density lipoprotein cholesterolHigh-density lipoprotein cholesterolConcentrations of high-density lipoprotein cholesterolLow HDL-C.Low HDL-CHeme oxygenase-1 pathwayTreatment period 1C-reactive proteinPlasma HDL-CTreatment period 2Improving endothelial functionEffects of niacinTransfer protein activityShort-term effectsReduced plasma concentrations
2013
Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp
Moura F, Carvalho L, Cintra R, Martins N, Figueiredo V, Quinaglia e Silva J, Almeida O, Coelho O, Sposito A. Validation of surrogate indexes of insulin sensitivity in acute phase of myocardial infarction based on euglycemic-hyperinsulinemic clamp. AJP Endocrinology And Metabolism 2013, 306: e399-e403. PMID: 24347056, DOI: 10.1152/ajpendo.00566.2013.Peer-Reviewed Original ResearchConceptsQuantitative insulin sensitivity check indexEuglycemic-hyperinsulinemic clampHomeostatic model assessmentHOMA-IRInsulin sensitivityMyocardial infarctionSurrogate indexHomeostatic model assessment of insulin resistanceModel assessment of insulin resistanceConsecutive nondiabetic patientsHomeostatic model assessment of insulin sensitivityAssessment of insulin resistanceST-segment elevation MISurrogate indexes of insulin sensitivityInsulin sensitivity check indexIndices of insulin sensitivityAcute phase of myocardial infarctionReceiver operating characteristic curveAcute MI patientsAssessment of insulin sensitivityPhase of myocardial infarctionGold standard reference methodBland-Altman plotsOperating characteristics curvePoor patient outcomesImpact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study
Moura F, Dutra-Rodrigues M, Cassol A, Parra E, Zago V, Panzoldo N, Alexandre F, Vieira I, Vendrame F, Virginio V, Castanho V, Danelon M, Nunes V, Leança C, Saraiva F, Coelho O, Nakandakare E, Quintão E, de Faria E, Sposito A. Impact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study. Chronobiology International 2013, 30: 1011-1015. PMID: 23837747, DOI: 10.3109/07420528.2013.793698.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAge FactorsAgedAged, 80 and overBiomarkersBrazilChildChild, PreschoolCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDyslipidemiasFemaleHumansInfantInfant, NewbornMaleMiddle AgedNonlinear DynamicsPeriodicityPrevalenceRisk FactorsSeasonsSex DistributionSex FactorsTime FactorsTriglyceridesYoung AdultConceptsLDL-CHDL-CLipoprotein cholesterolLipid profileLow-density lipoprotein cholesterolPlasma low-density lipoprotein cholesterolHigh-density lipoprotein cholesterolPrevalence of dyslipidemiaAnalysis of relative riskLipid profile parametersVariation of lipid profilePrimary care centersLipid parametersRate of goal achievementCross-sectional analysisConsecutive individualsRelative riskCardiovascular diseaseCare centerHealth checkupsMiddle-aged adultsTriglyceridesBiological rhythmsPreliminary dataPrevalence
2012
High-density lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: A study by euglycemic hyperinsulinemic clamp
Carvalho L, Martins N, Moura F, Cintra R, Almeida O, Quinaglia e Silva J, Sposito A, Group B. High-density lipoprotein levels are strongly associated with the recovery rate of insulin sensitivity during the acute phase of myocardial infarction: A study by euglycemic hyperinsulinemic clamp. Journal Of Clinical Lipidology 2012, 7: 24-28. PMID: 23351579, DOI: 10.1016/j.jacl.2012.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedBlood Chemical AnalysisFemaleGlucose Clamp TechniqueHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceLipoproteins, HDLMagnetic Resonance ImagingMaleMiddle AgedMyocardial InfarctionSeverity of Illness IndexSex FactorsTreatment OutcomeTriglyceridesConceptsAcute phase of MIHigh HDL groupHDL groupHDL-CPhase of MIMyocardial infarctionEuglycemic hyperinsulinemic clampAcute phaseInsulin sensitivityIS indexAssociated with increased morbidityConsecutive nondiabetic patientsHyperinsulinemic clampLevels of HDL-CPlasma levels of HDL-CST-segment elevation MIHigh-density lipoprotein levelsLow HDL groupHigh-density lipoprotein (HDLHDL-C levelsPlasma HDL-CWaist circumferenceRate of ISDecrease of insulin sensitivityLipoprotein (HDLEmergent cardiovascular risk factors in the very elderly
Moura F, Freitas W, Sposito A. Emergent cardiovascular risk factors in the very elderly. Expert Review Of Cardiovascular Therapy 2012, 10: 1221-1225. PMID: 23190062, DOI: 10.1586/erc.12.98.Peer-Reviewed Original Research
2011
High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction
Carvalho L, Cintra R, Moura F, Martins N, Quinaglia e Silva J, Coelho O, Sposito A, Group O. High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. Atherosclerosis 2011, 220: 231-236. PMID: 22018645, DOI: 10.1016/j.atherosclerosis.2011.09.044.Peer-Reviewed Original ResearchConceptsHDL-C levelsHDL-C quartilePlasma HDL-C levelsHDL-CC-peptideMyocardial infarctionAcute phaseStress hyperglycemiaInsulin sensitivityAssociated with HDL-C levelsConsecutive non-diabetic patientsNon-diabetic patientsAcute phase of MILow plasma HDL-C levelsAcute phase of myocardial infarctionST-segment elevationPhase of myocardial infarctionBeta-cell functionAssess insulin sensitivityPhase of MIImproved insulin sensitivityBlood glucose changesPlasma glucoseQuartilePlasma insulin